Prodotti GS / Area Kite
Kite Submits Supplemental Biologics License Application to U.S. FDA for Earlier Use of Yescarta in Large B-Cell Lymphoma
![Immagine News](/media/0icnkhat/cat-1.jpg?center=0.55476190476190479,0.25&mode=crop&width=722&height=442)
Kite has submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration for Yescarta to expand its current indication to include the treatment of adults with relapsed or refractory large B-cell lymphoma (LBCL) in the second-line setting. The sBLA filing is based on data from Kite’s landmark ZUMA-7 study. If approved, Yescarta would become the first CAR T-cell therapy for adults with LBCL who relapse after or are refractory to first-line therapy.
Grazie per il tuo feedback!